Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: A randomized trial

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Riccio, Eleonora ^a   Sabbatini, Massimo ^a   Bruzzese, Dario ^a   Capuano, Ivana ^a   Migliaccio, Silvia ^a   Andreucci, Michele ^b   Pisani, Antonio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALCITRIOL; CALCIUM; FERRITIN; HEMOGLOBIN; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; ERGOCALCIFEROL;

ADULT; ANEMIA; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; IRON BALANCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

C-REACTIVE PROTEIN; CALCITRIOL; ERGOCALCIFEROLS; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84924956343     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118174     Document Type: Article

References (37)

1. Lin R, White JH. The pleiotropic effects of Vitamin D. BioEssays 2003; 26: 21-28.
2. Nagpal S, Na SN, Rathrachelam R. Noncalcemic actions of Vitamin D Receptor ligands. Endocr Rev 2005; 26: 662-687. PMID: 15798098
3. Li YC, Kong J, Wei M, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 228-238.
4. Gravellone L, Rizzo MA, Martina V, Mezzina N, Regalia A, Gallieni M. Vitamin D receptor activators and clinical outcomes in chronic kidney disease. Int J Nephrol 2011; 2011: 419524. doi: 10.4061/2011/419524 PMID: 21647319
5. Lee JH O'Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency, an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 2008; 52: 1949-1956.
6. Andress DL. Vitamin D in chronic kidney disease. Best Pract Res Clin Endocrinol Metab 2011; 25: 647-655. doi: 10.1016/j.beem.2011.05.005 PMID: 21872805
7. Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency and inflammation and their association with hemoglobin levels in chronic kidney disease. Am J Nephrol 2009; 30: 64-72. doi: 0.1159/000202632 PMID: 19218791
8. Patel NM, Gutiérrez OM, Andress DL, Coyne DW, Levin A, Wolf M. Vitamin D deficiency and anemia in early chronic kidney disease. Kidney Int 2010; 77: 715-720. doi: 10.1038/ki.2009.551 PMID: 0130525
9. Sim JJ, Lac PT, Liu IL, Kumar VA, Kujubu DA, Rasgon SA. Vitamin D deficiency and anemia: a crosssectional study. Ann Hematol 2010; 89: 447-452. doi: 10.1007/s00277-009-0850-3 PMID: 19841921
10. Meguro S, Tomita M, Katsuki T, Kato K, Oh H, Ainai A, et al. Plasma 25-hydroxyvitamin D is independently associated with hemoglobin concentration in male subjects with type 2 diabetes mellitus. Int J Endocrinol 2011; 2011: 362981. doi: 10.1155/2011/362981 PMID: 21754928
11. Alon DB, Chaimovitz C, Dvilansky A, Lugassy G, Douvdevani A, Shany S, et al. Novel role of 1,25(OH)(2)D(3) in induction of erythroid progenitor cell proliferation. Exp Hematol 2002; 30: 403-409. PMID: 2031646
12. Aucella F, Scalzulli RP, Gatta G, Vigilante M, Carella AM, Stallone C. Calcitriol increases burst-forming unit-erythroid proliferation in chronic renal failure. A synergistic effect with r-HuEPO. Nephron Clin Pract 2003; 95: c121-c127. PMID: 14694273
13. Keithi-Reddy SR, Addabbo F, Patel TV, Mittal BV, Goligorsky MS, Singh AK. Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int 2008; 74: 782-790. doi: 10.1038/ki.2008.245 PMID: 18547996
14. Icardi A, Paoletti E, De Nicola L, Mazzaferro S, Russo R, Cozzolino M. Renal anemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. Nephrol Dial Transplant 2013; 28: 1672-1679. doi: 10.1093/ndt/gft021 PMID: 23468534
15. Baeke, Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006; 69: 33-43. PMID: 16374421
16. Brancaccio D, Cozzolino M, Gallieni M. Hyperparathyroidism and anemia in uremic subjects: a combined therapeutic approach. J Am Soc Nephrol 2004; 15(Suppl. 1): S21-S24. PMID: 14684666
17. Albitar S, Genin M, Fen-Chong M, Serveaux MO, Schohn D, Chuet C. High dose alfacalcidol improves anemia in patients on hemodialysis. Nephrol Dial Transplant 1997; 12: 514-518. PMID: 9075133
18. Saab G, Young DO, Gincherman Y, Giles K, Norwood K, Coyne DW. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 2007; 105: C132-C138. PMID: 17228173
19. Goicoecheca M, Vazquez MI, Ruiz Ma, Gomez-Campdera F, Perez-García R, Valderrábano F. Intravenous calcitriol improves anemia and reduces the need for erythropoietin in haemodialysis patients. Nephron 1998; 78: 23-27. PMID: 9453399
20. Capuano A, Serio V, Pota A, Memoli B, Andreucci VE. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients. J Nephrol 2009; 22: 59-68.
21. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J AmSocNephrol 1998; 9: 1427-1432.
22. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483-1490. PMID: 12631365
23. Monier-Faugere MC, Mawad H, Maaluche FF. Opposite effects of Calcitriol and Paricalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal-parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 1255-1260. PMID: 17942766
24. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 2: 249-255.
25. Guerrero F, Montes de Oca A, Aguilera-Tejero E, Zafra R, Rodríguez M, López I. The effect of vitamin D derivatives on vascular calcification associated with inflammation. Nephrol Dial Transplant 2012; 27: 206-2212. doi: 10.1093/ndt/gfr555 PMID: 22025118
26. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823-2828. PMID: 16316359
27. Bertoli M, Luisetto G, Ruffatti A, Urso M, Romagnoli G. Renal function during calcitriol therapy in chronic renal failure. Clin Nephrol 1990; 33: 98-102. PMID: 2311310
28. Perez A, Raab R, Chen TC, Turner A, Holick MF. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996; 134: 1070-78. PMID: 8763427
29. Kuhlman A, Haas CS, Gross ML, Reulbach U, Holzinger M, Schwarz U, et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286: F526-F533. PMID: 14600034
30. Matsui I, Hamano T, Tomida K, Inoue K, Takabatake Y, Nagasawa Y, et al. Active vitamin D and its analogue, 22-oxacalcitriol, ameliotare puromycin aminonucleoside-induced nephrosis in rats. Nephrol Dial Transplant 2009; 24: 2354-2361. doi: 10.1093/ndt/gfp117 PMID: 19297354
31. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009; 54: 647-652. doi: 10.1053/j.ajkd.2009.04.036 PMID: 19596163
32. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543-1551. doi: 10.1016/S0140-6736(10)61032-X PMID: 21055801
33. Bárány P. Inflammation, serum C-reactive protein, and erythropoietin resistance. Nephrol Dial Transplant 2001; 16: 224-227. PMID: 11158392
34. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33: 63-72. PMID: 9915269
35. Del Vecchio L, Pozzoni P, Andrulli S, Locatelli F. Inflammation and resistance to treatment with recombinant human erythropoietin. J Ren Nutr 2005; 15: 137-141. PMID: 15648023
36. Rathaus M. C-reactive protein in the assessment of iron status in patients on hemodialysis. G Ital Nefrol 2009; 26: 338-346;
37. Marckmann P, Agerskov H, Thineshkumar S, Bladbjerg EM, Sidelmann JJ, Jespersen J, et al. Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. Nephrol Dial Transplant 2012; 27: 3523-3531. doi: 10.1093/ndt/gfs138 PMID: 22822092